Pharmacokinetic Study of Frovatriptan Succinate Tablet After Single and Multiple Oral Doses in Chinese Healthy Subjects

Purpose: The present report describes findings from a Phase I clinical study that evaluated the single- and multiple-dose pharmacokinetics of frovatriptan succinate tablet in Chinese healthy subjects. Methods: A total of 24 healthy subjects were enrolled. In single-dose study, 2.5, 5, and 10 mg oral doses of frovatriptan succinate tablet were administrated. A 2.5 mg frovatriptan succinate tablet was administrated 12 times in 7 days in the multiple-dose study. Blood samples were collected at scheduled time points. Results: The results in single-dose study indicated that the blood levels were proportional to the administered dose, with the mean C-max and AUC(las)t ranging from approximately 6.27 ng/mL-17.35 ng/mL and 92.52 h.ng/mL - 287.40 h.ng/mL over the dose range. In the multipledose study, moderate drug accumulation was noted, which was attributable to forvatriptan's long t(1/2) of about 26.47 to 30.63 h. Gender differences were noticed in both single- and multiple-dose study; exposure PK parameters were consistently higher in female than in male. Conclusion: These pharmacokinetic evaluations in healthy Chinese subjects found that frovatriptan succinate tablet has an acceptable pharmacokinetic profile in Chinese subjects.

Automated summary

This report describes findings from a Phase I clinical study evaluating the pharmacokinetics of frovatriptan succinate tablet in Chinese healthy subjects. The results showed that the drug had acceptable pharmacokinetic profile in Chinese subjects, with gender differences in exposure parameters consistently higher in females than in males.